Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis

Archives of Dermatological Research

Volumn 304, Issue 3, 2012, Pages 203-208

  Yanaba, Koichi ^a   Asano, Yoshihide ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Arthritis; Digital ulcer; Platelet activating factor acetylhydrolase; Systemic sclerosis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINGER ULCER; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCAR; SCHOOL CHILD; SEROLOGY; SYSTEMIC SCLEROSIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ARTHRALGIA; ARTHRITIS; BIOLOGICAL MARKERS; FEMALE; FINGERS; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN ULCER;

EID: 84862895329     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-011-1196-y     Document Type: Article

References (29)

1. Bonavida B, Mencia-Huerta JM (1994) Platelet-activating factor and the cytokine network in inXammatory processes. Clin Rev Allergy 12:381-395
2. Bonin F, Ryan SD, Migahed L et al (2004) Anti-apoptotic actions of the platelet-activating factor acetylhydrolase I-2 catalytic subunit. J Biol Chem 279:52425-52436
3. Butler AR, Flitney FW, Williams DL (1995) NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci 16:18-22
4. Clements PJ, Lachenbruch PA, Seibold JR et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892-1896
5. Generini S, Matucci Cerinic M (1999) Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 455:93-100
6. Henderson WR Jr, Lu J, Poole KM, Dietsch GN, Chi EY (2000) Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inXammation and hyperreactivity in mouse asthma model. J Immunol 164:3360-3367
7. Hilliquin P, Menkes CJ, Laoussadi S, Benveniste J, Arnoux B (1992) Presence of paf-acether in rheumatic diseases. Ann Rheum Dis 51:29-31
8. Hofbauer B, Saluja AK, Bhatia M et al (1998) EVect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis. Gastroenterology 115:1238-1247
9. Karabina SA, Ninio E (2006) Plasma PAF-acetylhydrolase: an unfulWlled promise?. Biochim Biophys Acta 1761:1351-1358
10. Karasawa K (2006) Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta 1761:1359-1372
11. Kim JD, Baker CJ, Roberts RF et al (2000) Platelet activating factor acetylhydrolase decreases lung reperfusion injury. Ann Thorac Surg 70:423-428
12. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classiWcation, subsets and pathogenesis. J Rheumatol 15:202-205
13. Lupia E, Montrucchio G, Battaglia E, Modena V, Camussi G (1996) Role of tumor necrosis factor-and platelet-activating factor in neoangiogenesis induced by synovial Xuids of patients with rheumatoid arthritis. Eur J Immunol 26:1690-1694
14. Matsuzawa A, Hattori K, Aoki J, Arai H, Inoue K (1997) Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II. J Biol Chem 272: 32315-32320
15. Morgan EN, Boyle EM Jr, Yun W et al (1999) Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 100:II365-II368
16. Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78-85
17. Oshimoto H, Okamura S, Iida T, Ishikawa T, Hosaka K, Mori M (2005) Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inXammatory bowel disease. Tohoku J Exp Med 207:65-71
18. Packard CJ, O'Reilly DS, Caslake MJ et al (2000) Lipoproteinassociated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343:1148-1155
19. Palacios I, Miguelez R, Sanchez-Pernaute O, Gutierrez S, Egido J, Herrero-Beaumont G (1999) A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice. J Rheumatol 26:1080-1086
20. Prescott SM, Zimmerman GA, StaVorini DM, McIntyre TM (2000) Platelet-activating factor and related lipid mediators. Annu Rev Biochem 69:419-445
21. Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis: association with pulmonary Wbrosis. Arthr Rheum 37:391-394
22. Steen V, Denton CP, Pope JE, Matucci-Cerinic M (2009) Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 48(SUPPL. 3):iii19-iii24
23. Steen VD, Powell DL, Medsger TAJ (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthr Rheum 31:196-203
24. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classiWcation of systemic sclerosis (scleroderma). Arthr Rheum 23:581-590
25. Suematsu M, Wakabayashi Y, Ishimura Y (1996) Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovasc Res 32:679-686
26. Tamm M, Bihl M, Eickelberg O, Stulz P, Perruchoud AP, Roth M (1998) Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells. Am J Respir Cell Mol Biol 19:653-661
27. Tselepis AD, Elisaf M, Besis S, Karabina SA, Chapman MJ, Siamopoulou A (1999) Association of the inXammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthr Rheum 42:373-383
28. Umemura K, Kato I, Hirashima Y et al (2007) Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia. Stroke 38:1063-1068
29. Vergne P, Praloran V, Treves R, Denizot Y (1997) Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases. Mediat InXamm 6:241-242